Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zealand Pharma to present new data on its diabetes peptide therapeutics


Tuesday, 10 Jun 2014 07:19am EDT 

Zealand Pharma A/S:To present new beneficial data on four products from its portfolio of new diabetes peptide therapeutics at 74th Scientific Sessions of the American Diabetes Association (ADA) to be held in San Francisco, 13-17 June.Company's own-invented product, lixisenatide, once-daily prandial GLP-1 agonist for treatment of Type 2 diabetes, developed and marketed as Lyxumia under global license agreement with Sanofi, to feature in 11 abstracts.Abstracts include presentation of results from eight-week clinical study of lixisenatide versus liraglutide (Victoza).Two abstracts are also to be presented on LixiLan, fixed-ratio combination of lixisenatide with Lantus, including results from Phase IIb trial.